Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits

[1]  Xiaojing Xu,et al.  Carbohydrate-based adjuvants activate tumor-specific Th1 and CD8+ T-cell responses and reduce the immunosuppressive activity of MDSCs. , 2019, Cancer letters.

[2]  T. Billiar,et al.  iNOS promotes CD24+CD133+ liver cancer stem cell phenotype through a TACE/ADAM17-dependent Notch signaling pathway , 2018, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Sung-Hoon Kim,et al.  Melatonin disturbs SUMOylation‐mediated crosstalk between c‐Myc and nestin via MT1 activation and promotes the sensitivity of paclitaxel in brain cancer stem cells , 2018, Journal of pineal research.

[4]  N. Osman,et al.  Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma , 2017, International journal of molecular sciences.

[5]  Dawei Xu,et al.  WNT/β-Catenin Directs Self-Renewal Symmetric Cell Division of hTERThigh Prostate Cancer Stem Cells. , 2017, Cancer research.

[6]  J. Kirkwood,et al.  Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma , 2017, Scientific Reports.

[7]  P. Ott,et al.  Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma , 2017, Cancer and Metastasis Reviews.

[8]  Quentin Liu,et al.  Targeting NF-κB/AP-2β signaling to enhance antitumor activity of cisplatin by melatonin in hepatocellular carcinoma cells. , 2017, American Journal of Cancer Research.

[9]  M. Wick,et al.  Metastatic melanoma: Pathologic characterization, current treatment, and complications of therapy. , 2016, Seminars in diagnostic pathology.

[10]  Wenlin Huang,et al.  Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells , 2015, Oncotarget.

[11]  M. Schumacher,et al.  The progesterone receptor agonist Nestorone holds back proinflammatory mediators and neuropathology in the wobbler mouse model of motoneuron degeneration , 2015, Neuroscience.

[12]  A. Gasbarrini,et al.  High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour‐initiating properties of colon cancer stem cells , 2015, The Journal of pathology.

[13]  A. Rotte,et al.  Immunotherapy of melanoma: Present options and future promises , 2015, Cancer and Metastasis Reviews.

[14]  S. Leyvraz,et al.  High Expression of hTERT and Stemness Genes in BORIS/CTCFL Positive Cells Isolated from Embryonic Cancer Cells , 2014, PloS one.

[15]  Hemant R. Jadhav,et al.  Melatonin: functions and ligands. , 2014, Drug discovery today.

[16]  Sung-Hoon Kim,et al.  Melatonin Sensitizes H1975 Non-Small-Cell Lung Cancer Cells Harboring a T790M-Targeted Epidermal Growth Factor Receptor Mutation to the Tyrosine Kinase Inhibitor Gefitinib , 2014, Cellular Physiology and Biochemistry.

[17]  Tack-Joong Kim,et al.  Melatonin Combined with Endoplasmic Reticulum Stress Induces Cell Death via the PI3K/Akt/mTOR Pathway in B16F10 Melanoma Cells , 2014, PloS one.

[18]  Xiao-yi Qi,et al.  Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma , 2013, IUBMB life.

[19]  C. Alonso-González,et al.  Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells , 2013, Journal of pineal research.

[20]  Wenlin Huang,et al.  Melatonin potentiates the antiproliferative and pro‐apoptotic effects of ursolic acid in colon cancer cells by modulating multiple signaling pathways , 2013, Journal of pineal research.

[21]  Jian Huang,et al.  Cancer stem cell theory: therapeutic implications for nanomedicine , 2013, International journal of nanomedicine.

[22]  R. Reiter,et al.  Melatonin membrane receptors in peripheral tissues: Distribution and functions , 2012, Molecular and Cellular Endocrinology.

[23]  T. Gilmer,et al.  Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations , 2012, Molecular Cancer Therapeutics.

[24]  S. Kopetz,et al.  Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. , 2012, Cancer research.

[25]  Nikhil Wagle,et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[27]  H. Moch,et al.  Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. , 2011, Cancer research.

[28]  J. Engelman,et al.  Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers , 2011, Oncotarget.

[29]  J. Till,et al.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. 1961. , 2011, Radiation research.

[30]  B. Taylor,et al.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.

[31]  Irving L. Weissman,et al.  Human Melanoma Initiating Cells Express Neural Crest Nerve Growth Factor Receptor CD271 , 2010, Nature.

[32]  R. Reiter,et al.  Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK‐MEL‐1 cells , 2010, Journal of pineal research.

[33]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[34]  E. Grimm,et al.  NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. , 2009, The Journal of investigative dermatology.

[35]  Gideon Rechavi,et al.  MDR1 expression identifies human melanoma stem cells. , 2008, Biochemical and biophysical research communications.

[36]  Michael F Clarke,et al.  The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.

[37]  N. Ahmad,et al.  Melatonin in cancer management: progress and promise. , 2006, Cancer research.

[38]  L. Broemeling,et al.  Tumor iNOS predicts poor survival for stage III melanoma patients , 2006, International journal of cancer.

[39]  R. Reiter,et al.  RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line. , 2004, Cancer letters.

[40]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[41]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[42]  C. Peyssonnaux,et al.  The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.

[43]  J. Barrett,et al.  The oncostatic action of melatonin in an ovarian carcinoma cell line , 1999, Journal of pineal research.

[44]  A. Miles,et al.  Melatonin and psychiatry , 1988, Biological Psychiatry.

[45]  G. Maestroni,et al.  Role of the pineal gland in immunity Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone , 1986, Journal of Neuroimmunology.

[46]  Y. Grinevich,et al.  Melatonin, Thymic Serum Factor, and Cortisol Levels in Healthy Subjects of Different Age and Patients With Skin Melanoma , 1986, Journal of pineal research.

[47]  L. Wetterberg,et al.  Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome , 1985, Acta psychiatrica Scandinavica.

[48]  A. N. Taylor,et al.  Indole Compounds: Isolation from Pineal Tissue , 1965, Science.

[49]  J. Till,et al.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. , 1961, Radiation research.